Table 3. Intraindividual Patient Analyses.
| Genes | No. of Studies | Mean (Range) | Improvement (Range), % | |
|---|---|---|---|---|
| Baseline Values | Improvement | |||
| Motor improvement (UPDRS-III score)a | ||||
| PRKN | 2 | 53 (45-61) | 32 (26-38) | 64 (43-94) |
| LRRK2 | 2 | 48.5 (27-70) | 32.5 (19-46) | 68 (66-70) |
| PINK1 | 1 | 35.5 | 16.5 | 47 |
| SNCA | 1 | 22 | 9.5 | 43 |
| PRKN + PINK1 | 1 | 86 | 53 | 62 |
| LEDD reduction, mg | ||||
| PRKN | 2 | 700 (500-900) | 406 (220-592) | 55 (44-66) |
| LRRK2 | 2 | 875 (850-900) | 445 (400-490) | 51 (44-58) |
| PINK1 | 0 | NA | NA | NA |
| SNCA | 1 | 1250 | 790 | 63 |
| PRKN + PINK1 | 1 | 1181 | 691 | 59 |
Abbreviations: LEDD, levodopa equivalent daily dose; NA, not applicable; UPDRS-III, Unified Parkinson’s Disease Rating Scale Part III.
a
Motor improvement was defined as the change in the UPDRS-III score between the presurgical medication-off condition and the postsurgical medication-off/stimulation-on condition. The presurgical motor outcome (UPDRS-III score) associated with levodopa is reported in eTable 9 in the Supplement.